[1]申子龙,孙雪艳,赵文景.益气滋肾活血方治疗难治性膜性肾病脾肾两虚、瘀血阻络证疗效观察[J].西部中医药,2025,38(06):134-136.[doi:10.12174/j.issn.2096-9600.2025.06.26]
　SHEN Zilong,SUN Xueyan,ZHAO Wenjing.Clinical Observation on Benefiting-Qi, Nourishing-kidney and Activating-blood Prescription in the Treatment of Refractory Membranous Nephropathy of Spleen and Kidney Deficiency, and Blood Stasis Obstructing Collaterals Pattern[J].Western Journal of Traditional Chinese Medicine,2025,38(06):134-136.[doi:10.12174/j.issn.2096-9600.2025.06.26]
点击复制

益气滋肾活血方治疗难治性膜性肾病脾肾两虚、瘀血阻络证疗效观察()

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
38
期数:
2025年06期
页码:
134-136
栏目:
临床研究
出版日期:
2025-06-15

文章信息/Info

Title:
Clinical Observation on Benefiting-Qi, Nourishing-kidney and Activating-blood Prescription in the Treatment of Refractory Membranous Nephropathy of Spleen and Kidney Deficiency, and Blood Stasis Obstructing Collaterals Pattern
作者:
申子龙, 孙雪艳, 赵文景
首都医科大学附属北京中医医院，北京 100010
Author(s):
SHEN Zilong, SUN Xueyan, ZHAO Wenjing
关键词:
难治性膜性肾病; 单组试验目标值法; 抗磷脂酶A2受体抗体; 益气滋肾活血方
Keywords:
refractory membranous nephropathy; single-group target-value clinical trial; anti-PLA2R antibody; benefiting-;  nourishing-kidney and activating-blood prescription
分类号:
R256.51
DOI:
10.12174/j.issn.2096-9600.2025.06.26
文献标志码:
B
摘要:
目的观察益气滋肾活血方治疗难治性膜性肾病（refractory membranous nephropathy，RMN）脾肾两虚、瘀血阻络证临床疗效。 方法采用前瞻性、单组临床试验目标值法选取RMN患者34例，予益气滋肾活血方联合西医基础治疗，连续治疗24周。观察治疗第12周及治疗24周后患者主要疗效指标（总有效率）、次要疗效指标［血白蛋白、抗磷脂酶A2受体（anti-phospholipase A2 receptor，PLA2R）抗体、血肌酐、总胆固醇、甘油三酯、低密度脂蛋白］及安全性指标（血红蛋白）变化情况。 结果治疗第12周时，患者抗PLA2R抗体、血肌酐、甘油三酯、低密度脂蛋白水平均降低，但差异无统计学意义（P＞0.05），而总胆固醇水平与治疗前比较差异有统计学意义（P＜0.05）。治疗24周后，抗PLA2R抗体、总胆固醇、甘油三酯、低密度脂蛋白水平与治疗前比较差异有统计学意义（P＜0.05）。治疗第12周及治疗24周后，血红蛋白较治疗前降低，但差异无统计学意义（P＞0.05）。 结论益气滋肾活血方能够提高脾肾两虚、瘀血阻络型RMN患者临床疗效，其可降低抗PLA2R抗体水平，升高血清白蛋白水平，改善血脂代谢，有较好安全性。
Abstract:
ObjectiveTo observe clinical effects of benefiting-Qi, nourishing-kidney and activating-blood prescription in the treatment of refractory membranous nephropathy (RMN) of spleen and kidney deficiency, and blood stasis obstructing collaterals pattern. MethodsA prospective, single-group target-value clinical trial was adopted to choose 34 RMN patients, and they took the prescription orally, and basic therapy of Western medicine, for 24 weeks in a row. To observe the main index of clinical effects (total effective rate), the secondary indexes of clinical effects containing blood albumin, anti-PLA2R antibody, serum creatinine, total cholesterol, triglyceride and low density lipoprotein (LDL), and safety indicator (hemoglobin) after 12 weeks and 24 weeks of the treatment. ResultsAfter 12 weeks of the treatment, hemoglobin, anti-PLA2R antibody, serum creatinine, total cholesterol, triglyceride and LDL reduced, and the difference had no statistical meaning (P>0.05), while the difference had statistical meaning when the levels of total cholesterol were compared with these before treating (P<0.05). After treating for 24 weeks, the difference had statistical meaning in anti-PLA2R antibody, total cholesterol, triglyceride and LDL when compared with before the treatment (P<0.05). After 12 weeks and 24 weeks of the treatment, the levels of hemoglobin were lower than before the treatment, and the difference had no statistical meaning (P>0.05). ConclusionBenefiting-Qi, nourishing-kidney and activating-blood prescription could improve clinical effects of RMN patients of spleen and kidney deficiency, and blood stasis obstructing collaterals pattern, it could lower the levels of anti-PLA2R antibody, lift the levels of serum albumin and improve blood lipid metabolism with better safety.

备注/Memo

备注/Memo:
申子龙（1989—），男，博士学位，副主任医师。研究方向：张仲景学术思想与中医药防治慢性肾脏病。国家重点研发计划项目（2018YFC1704102）；北京市属医院科研培育计划项目（PZ2018012）。
更新日期/Last Update: 2025-06-15